These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32548120)

  • 41. Hsc70 rescues the synaptic vesicle trafficking defects caused by α-synuclein dimers.
    Brady EB; McQuillan M; Medeiros AT; Bubacco L; Sousa R; Lafer EM; Morgan JR
    MicroPubl Biol; 2023; 2023():. PubMed ID: 36938331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
    Muntané G; Dalfó E; Martinez A; Ferrer I
    Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies.
    Prots I; Grosch J; Brazdis RM; Simmnacher K; Veber V; Havlicek S; Hannappel C; Krach F; Krumbiegel M; Schütz O; Reis A; Wrasidlo W; Galasko DR; Groemer TW; Masliah E; Schlötzer-Schrehardt U; Xiang W; Winkler J; Winner B
    Proc Natl Acad Sci U S A; 2018 Jul; 115(30):7813-7818. PubMed ID: 29991596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. α-Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons.
    Froula JM; Henderson BW; Gonzalez JC; Vaden JH; Mclean JW; Wu Y; Banumurthy G; Overstreet-Wadiche L; Herskowitz JH; Volpicelli-Daley LA
    Acta Neuropathol Commun; 2018 May; 6(1):35. PubMed ID: 29716652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization.
    Samuel F; Flavin WP; Iqbal S; Pacelli C; Sri Renganathan SD; Trudeau LE; Campbell EM; Fraser PE; Tandon A
    J Biol Chem; 2016 Feb; 291(9):4374-85. PubMed ID: 26719332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis.
    Larsen KE; Schmitz Y; Troyer MD; Mosharov E; Dietrich P; Quazi AZ; Savalle M; Nemani V; Chaudhry FA; Edwards RH; Stefanis L; Sulzer D
    J Neurosci; 2006 Nov; 26(46):11915-22. PubMed ID: 17108165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. α-Synuclein: membrane interactions and toxicity in Parkinson's disease.
    Auluck PK; Caraveo G; Lindquist S
    Annu Rev Cell Dev Biol; 2010; 26():211-33. PubMed ID: 20500090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: Implications for visual manifestations of Parkinson's disease.
    Baksi S; Tripathi AK; Singh N
    Free Radic Biol Med; 2016 Aug; 97():292-306. PubMed ID: 27343690
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single-vesicle imaging quantifies calcium's regulation of nanoscale vesicle clustering mediated by α-synuclein.
    Cai B; Liu J; Zhao Y; Xu X; Bu B; Li D; Zhang L; Dong W; Ji B; Diao J
    Microsyst Nanoeng; 2020; 6():38. PubMed ID: 34567651
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion.
    von Einem B; Eschbach J; Kiechle M; Wahler A; Thal DR; McLean PJ; Weishaupt JH; Ludolph AC; von Arnim CAF; Danzer KM
    Aging (Albany NY); 2017 Jul; 9(7):1677-1697. PubMed ID: 28722658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
    Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
    J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Splice isoform and pharmacological studies reveal that sterol depletion relocalizes α-synuclein and enhances its toxicity.
    Valastyan JS; Termine DJ; Lindquist S
    Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3014-9. PubMed ID: 24516169
    [TBL] [Abstract][Full Text] [Related]  

  • 53. α-synuclein multimers cluster synaptic vesicles and attenuate recycling.
    Wang L; Das U; Scott DA; Tang Y; McLean PJ; Roy S
    Curr Biol; 2014 Oct; 24(19):2319-26. PubMed ID: 25264250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. alpha-Synuclein membrane interactions and lipid specificity.
    Jo E; McLaurin J; Yip CM; St George-Hyslop P; Fraser PE
    J Biol Chem; 2000 Nov; 275(44):34328-34. PubMed ID: 10915790
    [TBL] [Abstract][Full Text] [Related]  

  • 55. α-Synuclein induced cholesterol lowering increases tonic and reduces depolarization-evoked synaptic vesicle recycling and glutamate release.
    Lazarevic V; Yang Y; Paslawski W; Svenningsson P
    NPJ Parkinsons Dis; 2022 Jun; 8(1):71. PubMed ID: 35672421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy.
    Venezia S; Refolo V; Polissidis A; Stefanis L; Wenning GK; Stefanova N
    Mol Neurodegener; 2017 Jul; 12(1):52. PubMed ID: 28676095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
    Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
    BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
    Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
    J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies.
    Marvian AT; Koss DJ; Aliakbari F; Morshedi D; Outeiro TF
    J Neurochem; 2019 Sep; 150(5):535-565. PubMed ID: 31004503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.